Actively Recruiting
Randomized, Double-blind Study of SFG-02 Transdermal Patch Compared to Placebo in Adults With Underactive Bladder
Led by Juro Sciences Inc. · Updated on 2026-10-30
70
Participants Needed
16
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of a transdermal formulation called SFG-02 on Bladder Voiding Efficiency BVE in adults with Underactive Bladder UAB. This Phase 2a proof-of-concept study aims to assess both the impact on bladder function and the safety of the treatment compared to a placebo. Participants have symptoms like urinary hesitancy, straining to void, or weak urinary stream and meet specific bladder function criteria. Participants will undergo a 4-week placebo run-in period followed by 8 weeks of daily application of either the SFG-02 patch or a placebo patch. Each patch is worn for a full day, and participants will apply a new patch every day for a total treatment duration of 12 weeks. The study uses a randomized, double-blind design to compare the active drug to placebo. During the study, participants will visit the clinic every 2 to 4 weeks for checkups and tests. They will keep diaries to record bladder symptoms and the timing of patch changes. Researchers will monitor changes in Bladder Voiding Efficiency from baseline to the end of treatment as the primary outcome. Safety will also be assessed through laboratory tests and heart monitoring, with the entire participation lasting approximately 12 weeks.
CONDITIONS
Brief Title
A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)
Research Team
J
Juro Sciences
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here